# Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

> **NCT04175262** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 102 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma (mRCC)

## Interventions

- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT04175262
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-31
- **Primary completion:** 2020-03-09
- **Final completion:** 2020-03-09
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2023-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04175262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04175262, "Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04175262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*